The changing expectations shaping pharma outsourcing partnerships

Ask anyone involved in selecting a CDMO what matters and the answers are probably going to sound familiar: capability, capacity, cost, quality and timelines.

And of course, all of those things matter.

A sponsor needs to know that a potential partner can actually manufacture its product, has the right equipment and expertise, can meet the required timeline and can do it at a cost that makes commercial sense. Through stakeholder interviews, market research and wider industry conversations, it is becoming increasingly clear that those criteria only tell part of the story. Behind the RFPs, technical assessments, site visits and capacity discussions is a much simpler question: Does the sponsor have confidence in this CDMO’s ability to deliver?

That may sound like a softer consideration, but it is becoming increasingly important as outsourcing relationships become more complex and more strategic.

The ramarketing review cuts through the headlines to explore the developments shaping life sciences, with a different ramarketing expert each month providing context, commercial perspective and the stories that matter most.

If you’d like to receive updates straight to your inbox, sign up here.

Introducing September’s sector expert

With a background in biology and hands-on experience spanning technical, commercial, and marketing roles at leading CDMOs, Katie brings a unique understanding of the pharma outsourcing landscape to ramarketing.

Working closely with our strategy team, she combines her industry knowledge with market and buyer insights to help clients navigate challenges, identify opportunities, and make informed decisions that align with their commercial goals. Having worked on the CDMO side, Katie understands the realities our clients face and brings that perspective to developing strategies that support meaningful business growth.

Having capacity is not the same as being the right fit

There is no shortage of discussion about capacity in the CDMO world.

In 2026 alone, Vetter announced plans for a €480 million production facility in Germany while progressing a $285 million clinical manufacturing site in Illinois. INCOG BioPharma announced an approximately $200 million expansion of its injectable manufacturing campus in Indiana, while Cambrex is progressing a $120 million API capacity expansion in Iowa. These are only a handful of the projects announced this year, but they give a sense of just how much capital is being deployed to add manufacturing capacity across the outsourcing market.

There is good reason for this level of investment. In areas like complex injectables, advanced therapies and high-containment manufacturing, demand for the right kind of capacity continues to be strong. CPHI’s latest outsourcing outlook points to continued investment in highly specialized manufacturing capabilities as companies try to keep pace with increasingly complex pipelines.

But there is an important distinction. Available capacity and appropriate capacity are not the same thing.

An open manufacturing slot does not automatically make a CDMO the right fit for a specific product, development stage or commercial strategy. Sponsors are also looking at whether a partner has the technical depth, responsiveness and flexibility to support the program as it evolves.

That is where confidence starts to matter. The question is becoming less “can you do it?” and more “can we trust you to get us there?”

As sponsors rely more heavily on external partners across development and manufacturing, the cost of choosing the wrong fit becomes greater. Delays, poor communication or a lack of technical alignment can have consequences well beyond the manufacturing schedule.

That means stakeholder conversations are increasingly focused not just on what a CDMO can do, but on how it will work with the sponsor when challenges arise.

Questions increasingly center around things like:

• Will this team identify potential problems before they become bigger problems?
• Do they communicate clearly when something does not look right?
• Are they challenging an assumption if they believe there is a better approach?
• Will the technical team involved during selection still be engaged once the contract is signed?
• And perhaps most importantly, what happens when things do not go according to plan?

Those answers are much harder to capture in a capability deck. Yet they can have just as much influence on whether a sponsor feels comfortable moving forward.

Confidence starts well before the contract is signed

Trust and confidence are ultimately proven through project delivery, but sponsors are trying to assess those qualities long before a project begins. That can happen during a technical discussion, a site visit, a reference call or even an early sales conversation.

Sometimes a CDMO being willing to say, “This is not the best fit for us” can build more credibility than saying yes to everything.

That may seem counterintuitive in a competitive market, but there is real value in knowing where an organization genuinely adds value and being able to articulate it clearly.

More capabilities do not automatically equal more confidence

CDMOs have spent years expanding their footprints, adding services and building more integrated offerings. That can reduce handoffs and simplify outsourcing, but breadth alone does not make a partner more compelling.

For many sponsors, confidence comes from something more specific: clear evidence that a CDMO understands the challenge, knows where the risks are and has relevant experience solving similar problems. That can be far more persuasive than a long list of capabilities.

This creates an interesting challenge for CDMO marketing

Capabilities are relatively easy to market. A company can talk about site footprint, filling lines, batch sizes, reactor volumes, containment levels, packaging formats or installed technology.

Confidence is much harder to put on a website. How does a CDMO prove responsiveness or demonstrate technical judgment? How does it show that its teams communicate well when something changes? How does it give prospective customers confidence that risks will be identified early rather than once they become bigger problems?

This is where things like customer stories, case studies and expert-led content become invaluable. Technical content can do more than demonstrate knowledge. It can give a prospective customer a sense of how the experts behind the organization think. Even sales conversations can become more powerful when they acknowledge the complexity of the customer’s situation instead of immediately trying to reassure them that everything will be easy.

Marketing has an important role in helping reduce perceived risk before the sponsor ever walks through the door.

Confidence does not mean pretending there is no risk

This distinction is important. Pharmaceutical development and manufacturing are complicated. Things go wrong. Timelines change. Technical issues emerge. Regulatory expectations evolve. Sponsors do not need CDMOs to promise that none of those things will happen. Confidence comes from knowing that when uncertainty appears, the partner has the experience, processes and communication structures to manage it.

It is less about removing risk and more about demonstrating that the organization knows how to manage it.

So, what are sponsors really buying?

Capacity is not becoming less important. If anything, the continued investment across the CDMO sector proves the opposite. Capacity gets a company into the conversation. Capability shows that it can potentially do the work.

What increasingly differentiates one qualified partner from another is confidence in the organization behind those capabilities.

Confidence that the team understands the product. Confidence that it will communicate. Confidence that it will anticipate risk. Confidence that what was promised during the sales process can actually be delivered. And confidence that when something inevitably changes, the organization has the people and processes in place to respond.

In a market where so many CDMOs can make similar claims around capability, expertise and service, that may be where the real differentiation sits.